Mangoceuticals Partners with T7X to Become the First Nasdaq-Listed Company to Offer Tokenized Preferred Stock on the T7X Platform
Mangoceuticals announced a partnership with T7X to issue up to 1,000,000 shares of tokenized Series D Cumulative Convertible Preferred Stock at $10.00 per share, for gross proceeds of up to $10 million, in what it says would be the first security issued by a Nasdaq-listed company on the T7X platform. The preferred carries an 8% cumulative annual dividend on the $10.00 stated value, payable quarterly when declared. No common stock is issued at closing; conversion begins three years after issuance at a fixed price equal to 300% of the pre-qualification 10-day VWAP, subject to a floor price.
Key figures
- Deal Value Usd
- 10000000
- Offering Price
- 10
- Shares Offered
- 1000000
- Dividend rate
- 8% annual, cumulative, non-compounding, payable quarterly
- Offering type
- Tier 2 Regulation A (Form 1-A)
- Conversion start
- three years from issuance
- Conversion premium
- 300% of 10-day VWAP preceding SEC qualification, with floor price
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.